Purpose-We conducted a phase II multicentre study of gemcitabine in patients with anaplastic astrocytoma and glioblastoma multiforme at first relapse.
Introduction
Malignant gliomas (grade 3 anaplastic astrocytoma [AA] or grade 4 glioblastoma multiforme [GBM] ) are rapidly progressing primary brain tumors, which, in spite of advances in surgical, radiotherapy and chemotherapy treatments, remain associated with morbidity and mortality. Despite the current multimodality approach to therapy, the overall median survival for newly diagnosed patients is 10 months for patients with GBM and 2-3 years for those with AA [1] [2] [3] . At the time of recurrence, the median time to progression following treatment with currently available chemotherapeutic regimens ranges from 16-50 weeks for AA, and 8-25 weeks for GBM [4] . So far, no chemotherapeutic agent has emerged as a standard in the treatment of malignant gliomas at relapse.
Gemcitabine, an analogue of cytosine arabinoside, exerts its cytotoxicity mainly through the irreversible incorporation of the activated triphosphate into DNA, resulting in chain termination. Due to a number of self-potentiating mechanisms [5] [6] [7] [8] [9] , gemcitabine exhibits prolonged intracellular retention, a property likely partially responsible for gemcitabine's broad spectrum of activity [10] . In previous phase I and II trials, gemcitabine has shown a tolerable safety profile with little myelosuppression. It has activity in various malignancies with activity in small-cell lung cancer [11] , non-small-cell lung cancer [12] [13] [14] , ovarian [15] , cervical [16] , breast [17] , head and neck [18] , bladder [19, 20] and pancreatic cancers [21] [22] [23] . Further, investigators have recently demonstrated activity of gemcitabine in a number of human glioma cell lines [24] . Given the lack of an effective chemotherapeutic regimen for recurrent malignant gliomas, gemcitabine's properties made it a suitable drug to test for activity and tolerability in patients with AA or GBM at first relapse.
Patients and methods
This was a multicentre, phase II, open label, non-randomized trial designed to determine the efficacy and safety of gemcitabine in the treatment of patients with malignant glioma at first relapse. The Research Ethics Board of each participating institution approved the study. All patients gave written informed consent.
Patients
Eligible patients had histologjcally proven malignant glioma (grade 3 or 4). Anaplastic ependymoma and anaplastic oligodendrogliomas were specifically excluded. Patients with previously documented lower grade tumors were eligible if transformation to a higher-grade tumor was histologically documented. Recurrence or progression after failing surgery and radiotherapy for initial disease had to be documented by magnetic resonance imaging (MRI) or enhanced computerised tomography (CT). One prior adjuvant regimen of chemotherapy was accepted. At least six (for surgery and chemotherapy) or eight weeks (for radiation) had to have elapsed prior to trial entry. All patients had at least one bidimensionally measurable indicator lesion (at least 2 x 2 cm), and were on a stable dose of steroids for at least 14 days prior to entry. Patients were at least 18 years of age; had ECOG performance status ^3 ; had an estimated life expectancy of at least 12 weeks; had adequate bone marrow reserves (hemoglobin ^ 100 g/1, absolute granulocytes >1.5 x 1O 9 /1, platelets > 100 x 10 9 /l), normal coagulation profiles (PT/INR, PTT) and acceptable serum chemistries (serum calcium in normal range, serum creatinine =£l.5x, bilirubin <1.5x and AST ^ 3 x upper limits of normal). Treatment started within two working days of registration. Patients were excluded if they had: received chemotherapy or radiation for recurrent disease; had significant medical conditions; had previous invasive malignancies; or were pregnant, nursing or not practicing effective contraception if appropriate.
Assessments and treatment plan
Pre-treatment evaluation included a history and physical and neurological examination, laboratory and imaging studies and a baseline toxicity evaluation. Gemcitabine was administered at an initial dose of 1000 mg/m 2 by intravenous infusion over 30 minutes on days 1, 8 and 15 of each 28-day cycle, for a maximum of 6 cycles. The dose of gemcitabine was not escalated in this study but was reduced for significant hematologic and other toxicities. Toxicities were graded using the NCIC-CTG expanded common toxicity criteria. Evaluation during protocol treatment included history and physical examinations (including full clinical neurologic examination), biochemical profiles, imaging studies and toxicity assessments every four weeks. Hematology was done weekly. Central review of CT/MRI scans was to be carried out for any claimed responses. Response was assessed using standard NCIC-CTG criteria, but patients were not considered to have had complete or partial responses unless clinical neurologic assessment was improved or stable. Patients were monitored until death.
Statistics
Patients were considered evaluable for toxicity after the first dose of study drug, and for response if they had completed at least one cycle of gemcitabine. In order to minimize the expected number of patients treated in the event that the regimen proved to be very disappointing or highly effective, a two-stage design was used for patient accrual [25] . This study design, with 15 patients accrued in each stage, allowed for early termination if extreme results were observed. Accrual to the second stage would occur if at least one objective response was seen in the first 15 response-evaluable patients. Table 1 shows the characteristics of patients entered on the study. Twenty patients were registered, but one patient was deemed ineligible (steroids were initiated for symptom control on day 1). Of the 19 eligible patients included in the analyses, 7 were female and 12 male, with a median age of 50 years (range 28-71 years). Most patients (11 of 19 eligible) had an ECOG performance status of 2 or 3. There were 7 patients with A A, and 12 with GBM. Seven patients had received prior adjuvant chemotherapy, while all patients had received prior radiotherapy. All patients were receiving concomitant dexamethasone and 18 of the 19 eligible patients were receiving anti-convulsants. Forty-one cycles of chemotherapy were delivered; three patients received less than one full cycle due to early progression and eight patients received only one cycle. Only 1 patient received more than 4 cycles of therapy continuing on gemcitabine to a total of 11 cycles. Less than 60% of patients received ^ 90% of the planned dose intensity of gemcitabine. Treatment was discontinued in 15 patients because of objective (12 patients) or symptomatic (3 patients) disease progression, in 1 patient each due to toxicity (pneumocystis pneumonia described below), intercurrent illness (deep vein thrombosis), disease-related death and refusal to continue on protocol.
Results

Toxicity
Nineteen patients were evaluable for non-hematologic toxicity ( Table 2 ). The most common grade 3 or 4 adverse events were neurocortical (14 patients), neuromotor (11 patients) venous thrombosis (5 patients), urinary incontinence (4 patients) and visual disturbance (4 patients), usually attributed to disease progression or intercurrent illness. One patient (52-year-old male, unknown HIV status) developed Pneumocystis pneumonia and subsequent pulmonary embolus during his hospital stay. He improved on Septra and i.v. heparin and was eventually discharged from hospital. One patient had grade 3 oral candidiasis treated with parenteral antifungals. One patient died of a gastric bleed, considered related to steroid therapy, nine days after completion of one cycle (three doses) of gemcitabine. Platelet count was unknown.
Eighteen patients were evaluable for hematologic toxicity (Table 3) . Seven patients had granulocytopenia, which was grade 3 in one patient. Eleven patients had mild to moderate anemia, and thirteen patients had thrombocytopenia (grade 3 in 3 patients). Biochemical Table 2 . Non-hematologic toxicities. toxicity was mild, consisting of mild to moderate elevations of hepatic enzymes (Table 4) .
Objective response
Of the 19 eligible patients, four were inevaluable for response (3 had disease progression prior to completing first cycle, 1 patient had no follow-up CT). No responses were seen and therefore the study did not proceed to the second stage. Nine patients had stable disease (median duration 2.7 months, range 0.9-11.2 months) and 6 patients had a best response of progressive disease. One patient (AA; no previous chemotherapy) had both symptomatic improvement and initial radiologic improvement (but < partial remission) after six cycles of gemcitabine; the patient received an additional five cycles before being removed from protocol treatment with symptomatic progression.
Discussion
Gemcitabine, when delivered according to the present dosage and schedule regimen did not result in any objective responses. Gemcitabine has a broad spectrum of activity in solid tumors, as well as activity in preclinical glioma models. The lack of apparent activity thus warrants discussion. It is feasible that selection bias confounded the results. Patients had a minimum interval of eight weeks between completion of radiation and entry to the study and most had a performance status of 2 or 3. Patients with high-grade gliomas are known to have a rapidly deteriorating performance status [26] , and a delay of two months may have selected patients reaching a critical point in their disease. In our trial, 11 out of the 19 patients received only 1 complete or partial cycle of gemcitabine, due to disease progression rather than toxicity. Toxicity was generally mild. Gemcitabine pharmacokinetics were not assessed in this study, but drug interactions with other cytotoxic agents and anticonvulsants [27, 28] have been well described (all patients were receiving steroids and 18 of 19 anticonvulsants) raising the possibility of subtherapeutic dosing of gemcitabine; preclinical evidence suggests a lack of direct effect of anticonvulsants on the in vitro activity of gemcitabine [29] , although other workers suggest that dexamethasone may inhibit cytotoxicity of gemcitabine in in vitro glioma models [24] .
Our definition of response was quite rigorous, employing both a CT/MRI assessment of bidimensionally measurable lesions, a neurological evaluation [30] and strict accounting of corticosteroid administration. Despite this, 9 of the 15 evaluable patients had stable disease; in 1 patient, disease stabilized for over 11 months. However, as the median duration of stable disease was only 2.7 months (range 0.9-11.2) and as no objective responses were observed, the results of this trial do not support further investigation of gemcitabine in the treatment of high-grade gliomas.
